TCG Lifesciences Dinner - October, Zurich

12
October

05:00 PM CEST

The “heart of drug development” is to employ innovative technologies and collaborations across the globe, to assemble a powerful Drug Development Engine to accelerate candidates from drug discovery, PRD, scale-up through commercialization.

Radisson Blu Hotel Zurich Airport

DOWNLOAD THE BROCHURE

WHAT TO EXPECT

Overview of Discussion

Seamless global strategy for NCE development / and API supply chain by optimizing technology, providing collective expertise, and reducing the delivery time and cost – an unmet need

The “heart of drug development” is to employ innovative technologies and collaborations across the globe, to assemble a powerful Drug Development Engine to accelerate candidates from drug discovery, PRD, scale-up through commercialization. The best way to increase the valuation of drug discovery and development pipeline and company’s portfolio is to accelerate their milestones, reduce costs while maintaining quality. Today’s CDMO industry is lacking a unique collective expertise in one place, utilizing ground-breaking technologies for the synthesis of architecturally complex molecules that can intercept any molecule, at any stage of development. Ultimately the know-how of phase appropriate execution, ‘shaving’ months off the development cycle time and a “one stop shop” of delivery of entire CMC management is an unmet need.

Agenda

Swapan Bhattacharya, Managing Director, TCG Lifesciences Pvt. Ltd.

Subho Roy, Ph.D, Vice President – Business Head

Clinivent Research Pvt. Ltd, A 100% subsidiary of TCG Lifesciences

Big Pharma training with Biotech mentality to “Accelerate Molecules to Medicines”

Solving complicated CMC problems for NCEs adopting “First Time Right” techniques for First in Human studies
Reducing timelines by utilizing optimized “Drug Development Engine”
Leveraging innovative technologies embedded in Process Research and Development for API
Utilization of dynamic cost structure model
Tapping global resource pool
US management oversight operation
24 hr/day for solving problems and deliveries
Smooth tech transfer for API in a global setting
Implementing collective expertise of globally based scientists, scientific project managers and engagement
with client-based approach
Maintaining transparency and IP protection

Joseph D. Armstrong, III, Ph.D, COO, TCG GreenChem, Inc. (NJ & VA, USA)

Subho Roy, Ph.D. Vice President – Business Head, Clinivent Research Pvt. Ltd, A 100% subsidiary of TCG Lifesciences

Swapan Bhattacharya, Managing Director
TCG Lifesciences Pvt. Ltd.

Dr. Gopal Sirasani, Director, CDMO Business Development and Technical Operations
TCG GreenChem

WHY BOOK YOUR V.I.P SEAT NOW?

You will be amongst 10-15 Industry thought leaders from a mix of large Pharmaceutical Institutions ensuring you are given ample opportunity to raise questions and contribute from a strategic perspective. You can wine, dine and network with industry leaders who face common challenges in 60-minute roundtable discussions that enable you to share ideas and lessons learned. The dinner will be facilitated by expert moderators, these sessions provide a valuable dialogue with peers on current challenges and topical issues. There is no media, marketing or press, just pure and honest discussion to help solve your key strategic challenges for the next 3-9 months.rnrn

Meet the Facilitators

The Dinner will be lead by our expert facilitators

Dr. Joseph D. Armstrong, III, Ph.D

COO TCG GreenChem, Inc (NJ & VA, USA)

Dr. Armstrong is a high energy scientific and executive leader with 28 years of experience at Merck & Co., Inc. in Process Research, Formulation Development and Project Management with deep knowledge and experience of all drug discovery and development processes to support IND to NDA filings. As the Merck Preclinical Integration Lead (Process R&D, Formulation R&D, DMPK, Safety Assessment, and Clinical Supplies) for the merger with Schering Plough, created a multidisciplinary organization that leveraged development knowledge to accelerate identification of Preclinical Candidates and their rapid entry into the clinic and beyond. He led the cross-functional team that filed the drug JanuviaTM for the treatment of type II diabetes in < 4 years by executing new green and sustainable technologies and strategies. He led the Process R&D Team that discovered the novel asymmetric hydrogenation process for the preparation of Sitagliptin, the active ingredient in JanuviaTM . This team received the Thomas Edison award, the EU IChemE Aztra-Zeneca Award for Green Chemistry and Engineering and the US Presidential Green Chemistry Challenge Award.

Dr. Sanjoy Kumar Mahanty, Ph.D

Vice President, Head of Business Development TCG Lifesciences Pvt. Ltd

Dr. Subho Roy, Ph.D

Vice President – Business Head Clinivent Research Pvt. Ltd, A 100% subsidiary of TCG Lifesciences

Dr. Subho Roy Joined the group in 2002 and has been one of the key leadership members responsible for the growth of the company. He holds a Ph.D degree from Indian Institute of Chemical Technology, working with Dr. A.V.Rama Rao, on synthesis of natural products of biological importance and subsequently spent few years at the University of Kansas, Lawrence, USA, working with Dr. Gunda Georg for his post-doctoral studies. He has more than 20 years of Industrial experience of progressing small molecules coming out of R&D through various phases of development and taking them all the way to commercialization. He is a specialist in new process development, optimization and various other aspects of CMC. Dr. Roy has several publications to his credit and holds several European and US patents. He has played a key role in conceptualizing and designing of the manufacturing facility, “Clinivent Research Pvt. Ltd.”, a 100% subsidiary of <a href="https://www.tcgls.com/">TCG Lifesciences</a>, which has successfully completed US FDA inspection.

Vishal Rajput, Ph.D

Vice President, Business Development TCG Lifesciences Pvt. Ltd.

Swapan Bhattacharya

Managing Director TCG Lifesciences Pvt. Ltd.

Swapan Bhattacharya is the Managing Director of TCG Lifesciences (TCGLS) and is responsible for the executive leadership and overall management of the company. He co-founded TCGLS in 2001 and has taken the Company to a global leadership position in the research services space. He is also a key member of the Governing Council of the TCG Centers for Education and Research in Science and Technology, a not-for-profit institute in the process of spawning multiple centers of excellence in the frontier fields of translational neuroscience and oncology, AI and quantum computing. He has been associated with the TCG Group since 1995 and has spearheaded the group’s investments in India and its entry into life sciences domains from 1998. His professional career has spanned across the globe for about 40 years. Prior to joining the Group, he has held positions with PaineWebber Inc. as Senior Vice President and as Consultant to the US Nuclear Regulatory Commission. Over the years, he has held leadership committee positions in US India Business Council, FICCI, AMCHAM and Assocham; several board positions; and received excellence awards. He holds a bachelor’s degree in engineering from the Indian Institute of Technology, Kharagpur, a master’s degree from the Virginia Polytechnic Institute and State University, U.S.A and an MBA from Kellogg School of Management, Northwestern University, U.S.A. He received the Lester Cunningham Award for academic excellence at Northwestern.

Dr. Gopal Sirasani, Ph.D

Associate Vice President TCG GreenChem, Inc.

More about TCG Lifesciences

More information

At TCG, we address these needs with a proven strategy utilizing the following inherent strengths: Top tier and experienced people from big-Pharma , High end technology platforms and science, like continuous chemistry, catalysis , Large PRD group working across the globe , Operational synergies amongst group companies , Trust-based client relations and depth of engagement spanning two decades and World class facilities and infrastructure. We deliver integrated end-to-end solutions to the global life sciences’ industries.

Further Information

Interested in attending this virtual roundtable or running your own? Drop us a message today and we will get in touch.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D TCG Zurich

TCG Lifesciences Dinner – October

The “heart of drug development” is to employ innovative technologies and collaborations across the globe, to assemble a powerful Drug Development Engine to accelerate candidates from drug discovery, PRD, scale-up through commercialization.

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Radisson Blu Hotel Zurich Airport

Overview of Discussion

Agenda

Registration, Networking & Cocktails

Welcome & Introductions

Roundtable Discussion Big Pharma training with Biotech mentality to “Accelerate Molecules to Medicines”

Dinner

Roundtable Discussion Continue the topic Big Pharma training with Biotech mentality to “Accelerate Molecules to Medicines”

Closing Remarks, Coffee & Cognacs

WHY BOOK YOUR V.I.P SEAT NOW?

Meet the Facilitators

Dr. Joseph D. Armstrong, III, Ph.D

Dr. Sanjoy Kumar Mahanty, Ph.D

Dr. Subho Roy, Ph.D

Vishal Rajput, Ph.D

Swapan Bhattacharya

Dr. Gopal Sirasani, Ph.D

More about TCG Lifesciences

Further Information

Select days you wish to attend You can add multiple days

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Psychiatry

Dermatology

Internal diseases

Respiratory

Diabetes

Metabolic diseases

Rheumatology

Endocrinology

Nephrology

Surgery

ENT

Neurology

Urology

Gastroenterology

Oncology

Vaccines

Haematology

Ophthalmology

Thrombosis

Rare Diseases

This is required field*

0-10

10-50

50-100

100-500

500+

This is required field*

Under £100,000

£100,000 - £500,000

£500,000 - £1,000,000

£1,000,000 - £5,000,000

£5,000,000 - £10,000,000

£10,000,000 +

This is required field*

Discovery to Development

Radisson Blu Hotel Zurich Airport